| abstract |
The present invention relates to a compound of formula (I), Where X 1 , X 2 and X 3 are independently N or CH; the restriction is that at least two of X 1 , X 2 and X 3 are N; Y is N or CH; R 1 and R 2 are each other Morpholinyl independently of (i) formula (II) Where the arrow represents the bond in formula (I); and wherein R 3 and R 4 are independently H, C 1 -C 3 alkyl, C 1 -C 2 fluoroalkyl optionally substituted with one or two OH , C 1 -C 2 alkoxy, C 1 -C 2 alkoxy C 1 -C 3 alkyl, CN or C (O) OC 1 -C 2 alkyl; or R 3 and R 4 together form The following divalent residues -R 5 R 6- : C 1 -C 3 alkylene substituted with 1 to 4 Fs as appropriate, -CH 2 -O-CH 2- , -CH 2 -NH-CH 2 -Or any of the following structures Where the arrow represents the bond in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl optionally substituted with 1 to 3 R 7 ; wherein R 7 is The second occurrence is independently C 1 -C 3 alkyl, C 1 -C 2 fluoroalkyl, C 1 -C 2 alkoxy, C 1 -C 3 alkyl, C, optionally substituted with one or two OH 3 -C 6 cycloalkyl; or two R 7 substituents taken together to form a C 1 -C 3 alkylene, -CH 2 -O-CH 2 -or -O, optionally substituted with 1 to 4 F -CH 2 CH 2 -O- divalent residue -R 8 R 9- ; the restriction is that at least one of R 1 and R 2 is a morpholinyl group of formula II; and its prodrugs, metabolites, Tautomers, solvates, and pharmaceutically acceptable salts are used to prevent or treat neurological disorders in a subject. |